RESUMO
Ampullary carcinomas are rare but increasing in incidence. Ampullary cancers have molecular alterations that guide choice of therapy, particularly in nonresectable cases. These alterations can be more common by subtype (intestinal, pancreaticobiliary, or mixed), and next-generation sequencing is recommended for all patients who cannot undergo surgery. In this article, we review the approach to tissue acquisition and consideration for molecular testing. Common molecular targets of interest in ampullary cancer are also discussed in this review, including HER2/ERBB2, HER3, tumor mutational burden, microsatellite instability, KRAS, and germline BRCA and ATM mutations, along with emerging and rarer alterations.
Assuntos
Ampola Hepatopancreática , Neoplasias do Ducto Colédoco , Terapia de Alvo Molecular , Humanos , Ampola Hepatopancreática/patologia , Terapia de Alvo Molecular/métodos , Neoplasias do Ducto Colédoco/terapia , Neoplasias do Ducto Colédoco/diagnóstico , Neoplasias do Ducto Colédoco/genética , Neoplasias do Ducto Colédoco/patologia , Mutação , Biomarcadores Tumorais/genéticaRESUMO
This cohort study examines the rates of neutropenic feverassociated admissions and outpatient antibiotic use among patients with cancer receiving chemotherapy before and during the COVID-19 pandemic.